A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study

2001 ◽  
Vol 108 (8) ◽  
pp. 835-839 ◽  
Author(s):  
Robert F. Burrows ◽  
Eng T. Gan ◽  
Alexander S. Gallus ◽  
Euan M. Wallace ◽  
Elizabeth A. Burrows
Keyword(s):  
Molecular Weight ◽  
Pilot Study ◽  
Caesarean Section ◽  
Low Molecular Weight Heparin ◽  
Controlled Trial ◽  
Low Molecular Weight ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial

Blood ◽  
2015 ◽  
Vol 125 (14) ◽  
pp. 2200-2205 ◽  
Author(s):  
Elisabeth Pasquier ◽  
Luc de Saint Martin ◽  
Caroline Bohec ◽  
Céline Chauleur ◽  
Florence Bretelle ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Recurrent Miscarriage ◽  
Controlled Trial ◽  
Low Molecular Weight ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Live Birth Rates ◽  
Key Points ◽  
Unexplained Recurrent Miscarriage

Key Points The use of low-molecular-weight heparin did not improve live-birth rates in nonthrombophilic women with consecutive recurrent miscarriage. Prophylactic doses of low-molecular-weight heparin should no longer be prescribed in this clinical setting.

A Double-Blind Randomized Placebo Controlled Trial of Thromboprophylaxis in Major Elective General Surgery Using Once Daily Injections of a Low Molecular Weight Heparin Fragment (Fragmin)

1989 ◽  
Vol 62 (04) ◽  
pp. 1046-1049 ◽  
Author(s):  
Paul A Ockelford ◽  
Janet Patterson ◽  
Allan S Johns
Keyword(s):  
Molecular Weight ◽  
General Surgery ◽  
Low Molecular Weight Heparin ◽  
Controlled Trial ◽  
Active Agent ◽  
Daily Injection ◽  
Low Molecular Weight ◽  
Double Blind ◽  
Once Daily ◽  
Double Blinded

SummaryThe safety and efficacy of the low molecular weight heparin fragment (Fragmin) administered as a single daily injection of 2,500 anti Xa units has been evaluated in 183 patients undergoing major elective general surgery. The study was double-blinded and placebo controlled. The active agent, or placebo, was given subcutaneously with the preoperative medication and continued postoperatively for 5-9 days. Ninety five patients received Fragmin and 88 were randomized to receive the placebo. The clinical characteristics of the two treatment groups were similar. Fragmin significantly reduced the incidence of deep venous thrombosis, as detected by a positive 125I fibrinogen leg scan, relative to the placebo treated patients (4/95, 4.2%; v. 14/88, 15.9%; p = 0.008). The thrombotic events occurred predominantly (73%) amongst patients with malignancy. Haemorrhagic endpoints necessitating discontinuation of the trial treatment were 4% in each group. No severe adverse reactions or drug related deaths occurred. These results indicate that 2,500 anti Xa units of Fragmin given only once daily is effective thromboprophylaxis for patients undergoing major elective abdominal surgery.

Low-molecular-weight-heparin in radial artery occlusion treatment: the LOW-RAO randomized study

2021 ◽  
Author(s):  
Matthaios Didagelos ◽  
Areti Pagiantza ◽  
Thomas Zegkos ◽  
Christos Papanastasiou ◽  
Konstantina Zarra ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Radial Artery ◽  
Low Molecular Weight Heparin ◽  
Controlled Trial ◽  
Randomized Study ◽  
Coronary Intervention ◽  
Artery Occlusion ◽  
Low Molecular Weight ◽  
Open Label ◽  
Radial Artery Occlusion

Radial artery occlusion (RAO) is the commonest complication of transradial catheterization. There is no evidence-based therapy, in the frame of a randomized control study, for the treatment of RAO. The purpose of the LOW-RAO study is to question the hypothesis if low-molecular-weight heparin is effective in the treatment of RAO after transradial coronary catheterization (both angiography and percutaneous coronary intervention). It is a prospective, open label, randomized controlled trial that will randomize 60 patients with RAO, irrespective of symptoms, into two groups, one receiving anticoagulation with low-molecular-weight heparin and the other receiving no treatment. The primary end point is improvement in radial artery patency rate at 4 weeks after the procedure. Trial registration number: NCT04196309 (ClinicalTrials.gov)

Sign in / Sign up

Export Citation Format

Share Document